Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun H J, von Broen I M, Fischer J T, Gramatzki M
Abt. Immunologie und Transfusionsmedizin, Zentrum Innere Medizin und Dermatologie Med. Hochschule Hannover, FRG.
Onkologie. 1990 Dec;13(6):458-60. doi: 10.1159/000216820.
277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-alpha maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was greater than 36 months in stage II and 11 months in stage III patients.
277例1期（n = 33）、2期（n = 106）和3期（n = 138）未经治疗的多发性骨髓瘤患者进入研究。2期患者中，初始或观察期间出现肿瘤进展的患者（n = 64）接受了米泊蒽醌联合泼尼松（MivP）治疗（缓解率：61%）。138例3期患者被随机分配接受MivP或长春新碱、卡莫司汀、阿霉素、美法仑、地塞米松（VBAMDex）治疗。接受MivP治疗的患者缓解率为51%，而接受VBAMDex治疗的患者为70%。71例疾病稳定的2期和3期缓解患者被随机分配接受α干扰素维持治疗或不接受维持治疗。两组在7个月后的复发率均为50%。2期患者75%的生存率大于36个月，3期患者大于11个月。
